Telix Pharmaceuticals Ltd
Telix Pharmaceuticals Ltd is a Healthcare company operating in Biotechnology with a $3.39B market cap.
Most recent earnings call: Q4 FY25 on Feb 20, 2026.
8 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-06-21.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Reported quarters with consensus, surprise, and 1-day reaction context.
Spoken Alpha tracks TLX's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 70% of the time
SamplePeers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for TLX.
$ curl https://api.spokenalpha.com/v1/companies/TLXFAQ
Spoken Alpha indexes TLX's earnings call transcripts at https://spokenalpha.com/companies/TLX. Each call links to attributed speakers and parsed analyst Q&A. Telix Pharmaceuticals Ltd's own investor relations page is at https://ir.telixpharma.com/resources/investor-resources.
Telix Pharmaceuticals Ltd (TLX) held its most recent earnings call on 2026-02-20, covering fiscal Q4 2025.
Telix Pharmaceuticals Ltd (TLX) operates in the Healthcare sector (Biotechnology industry).
When a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2025 | $3.56 | $3.21 | +11.0% | +2.1% | -0.7% |
| Q4 FY2025 | $3.71 | $3.38 | +9.8% | 0.0% | -1.8% |
| Q3 FY2025 | $3.92 | $3.47 | +12.9% | -2.2% | -5.1% |
| Q2 FY2025 | $4.13 | $3.51 | +17.8% | -2.7% | -3.8% |
| Q1 FY2024 | $3.58 | $3.35 | +6.8% | +1.2% | +3.5% |
| Q4 FY2024 | $4.07 | $3.46 | +17.7% | -5.2% | -7.5% |
| Q3 FY2024 | $3.98 | $3.59 | +10.9% | -4.5% | -6.2% |
| Q2 FY2024 | $4.13 | $3.54 | +16.7% | +0.5% | -2.0% |
| Q1 FY2023 | $4.10 | $3.43 | +19.6% | -4.8% | -3.1% |
| Q4 FY2023 | $3.71 | $3.51 | +5.7% | -6.6% | -9.3% |